Lucent Diagnostics Partners with Tempus AI to Bring Blood-Based Alzheimer's Testing to Clinical Workflows
Tags AI · Enterprise
Lucent Diagnostics (Quanterix) announced a collaboration with Tempus AI to integrate the LucentAD Complete multi-biomarker blood test into Tempus' clinical ordering platform for neurologists. Tempus will build a Tempus Next care gap program to identify patients eligible for Alzheimer's biomarker testing. More than 7 million Americans live with Alzheimer's, but only a small fraction are currently evaluated for approved treatments. Quanterix reported Q1 2026 revenue of $36.4 million (+20% YoY) and is targeting FDA clearance for LucentAD Complete in H2 2026.
Technical significance
Blood-based Alzheimer's biomarker testing could dramatically expand screening access, as current methods (PET scans, lumbar punctures) are expensive and invasive. Tempus' integration into clinical ordering platforms means the test could reach millions of patients through existing physician workflows. The partnership also signals Tempus' strategic expansion beyond its oncology core into neurology.